Skip to main content

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting · Phase 3 · NCT06203210

Conditions: Small Cell Lung Cancer

At a glance

Research payments reported, 2025
$1.5M
U.S. investigators named
33
Sites paid
38
Planned or actual enrollment
540

About the trial

Sponsor
Daiichi Sankyo (with Merck Sharp & Dohme LLC)
Tested
Ifinatamab deruxtecan (drug), Topotecan (drug), Amrubicin (drug), Lurbinectedin (drug)
Dates
Started 2024-05-21; completion 2029-12-01
Results posted
Not yet

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $1.5M in research payments for this study in 2025 (1,364 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.